Filing Flows › Arcus Biosciences (RCUS) › Guidance & outlook
Arcus Biosciences (RCUS) guidance and outlook
Arcus Biosciences (RCUS) gave its guidance on Nov 4, 2026: Revenue (segment) $70.0M–$75.0M for FY2026. Arcus Biosciences' 10-Q filed Nov 4, 2026 makes 9 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $70.0M–$75.0M | new |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- We intend to use our website www.arcusbio.com as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
- Such disclosures will be included on the company’s website under the heading "Investors & Media." Accordingly, investors should monitor such portions of the company’s website, in addition to following the company’s press releases, SEC filings and public conference calls and webcasts (if any).
- Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our immunology programs.
- We have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future.
- We record advance payments for services that will be used or rendered for future R&D activities as prepaid expenses and recognize them as an expense as the related services are performed.
- We expect R&D expenses to remain relatively consistent in the near term, as increased investment in the development of casdatifan and the advancement of our small-molecule immunology programs continues to offset the decreases in our other programs.
- We do not anticipate significant changes in our G&A expenses in the near-term.
- We will need substantial additional funding to support our continuing operations and pursue our development strategy.
- Until such time that we can generate significant revenue from sales of our investigational products, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including existing or potential collaborations with other companies or other strategic transactions.
Arcus Biosciences' latest quarter
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Arcus Biosciences raise or lower its guidance?
Arcus Biosciences (RCUS) gave its guidance on Nov 4, 2026: Revenue (segment) $70.0M–$75.0M for FY2026.
What does Arcus Biosciences expect?
We intend to use our website www.arcusbio.com as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website under the heading "Investors & Media." Accordingly, investors should monitor such portions of the company’s website, in addition to following the company’s press releases, SEC filings and public conference calls and webcasts (if any). Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clin
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.